Osimertinib-induced lymphocytopenia and pneumocystis jirovecii pneumonia.

Takechi, H; Endoh, H; Hata, Y; Wasamoto, S; Yanagisawa, S

Takechi, H; Endoh, H; Hata, Y; Wasamoto, S; Yanagisawa, S.

Afiliação

Takechi H; Department of Respiratory Medicine, Saku Central Hospital Advanced Care Center, 3400-28 Nakagomi, Saku-city, Nagano 385-0051, Japan.
Endoh H; Department of Thoracic Surgery, Saku Central Hospital Advanced Care Center, 3400-28 Nakagomi, Saku-city, Nagano 385-0051, Japan.
Hata Y; Department of Respiratory Medicine, Saku Central Hospital Advanced Care Center, 3400-28 Nakagomi, Saku-city, Nagano 385-0051, Japan.
Wasamoto S; Department of Respiratory Medicine, Saku Central Hospital Advanced Care Center, 3400-28 Nakagomi, Saku-city, Nagano 385-0051, Japan.
Yanagisawa S; Department of Respiratory Medicine, Saku Central Hospital Advanced Care Center, 3400-28 Nakagomi, Saku-city, Nagano 385-0051, Japan. Electronic address: yngsw-0829@umin.org.

Pulmonology ; 28(5): 403-405, 2022.

Article em En | MEDLINE | ID: mdl-35701337

Assuntos

Leucopenia; Linfopenia; Pneumonia por Pneumocystis; Acrilamidas; Compostos de Anilina/efeitos adversos; Humanos; Indóis; Linfopenia/induzido quimicamente; Pneumonia por Pneumocystis/diagnóstico; Pneumonia por Pneumocystis/tratamento farmacológico; Pirimidinas

Palavras-chave

Epidermal growth factor receptor (EGFR)-mutation; Lung adenocarcinoma; Lymphocytopenia; Osimertinib; Pneumocystis jirovecii pneumonia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pneumonia por Pneumocystis / Leucopenia / Linfopenia Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google